Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Carbocisteine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Carbocisteine 250 mg/5 ml syrup (called Carbocisteine in this leaflet) contains a medicine called carbocisteine. This belongs to a group of medicines called "mucolytics' used in the antibacterial treatment of respiratory infections, in the presence of bronchial hypersecretion. It works by making the mucus (catarrh) less sticky. This makes the mucus easier to exit when coughing. Carbocisteine syrup is used for problems in the airways when there is too much mucus or when it is too sticky.
e Carbocisteine Do not take Carbocisteine:
It is not recommended to use in the pregnant woman, especially during the first 3 months of pregnancy, even though no teratogenic effects have been detected. Breastfeeding: It is not recommended to use during breastfeeding because there are no safety data, concerning the passage of carbocisteine into breast milk. Considering its low toxicity, ifthe mother is treated with this product, the potential risks for the child seem negligible. Driving and using machines No effects were seen on the ability to drive and use machines. Carbocisteine contains Sucrose For use in children This medicine contains 2.8 g of sucrose in each 5 ml paediatric dose. May be harmful to teeth. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product. For use in adults This medicine contains 8.4 g of sucrose in each 15 ml adult dose. This should be taken into account in patients with diabetes mellitus. Ifyou have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product. Carbocisteine contains methyl parahydroxybenzoate. May cause allergic reactions (possibly delayed). 3. How to take Carbocisteine Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Using the measuring device (oral syringe with 5 ml capacity), measure the quantity that you will need whether you are an adult or a child, according to the general posology. The syringe for oral administration is graduated per 0.25 ml. One graduation, 0.25 ml corresponds to 12.5 mg of carbocisteine.
the syringe:
Step 1: Check the measurements on the side of the syringe to see how much to fill it. Step 2: Push the syringe's plunger all the way down. Then put the tip of the syringe into the medicine bottle. Step 3: Slowly pull back on the plunger until the syringe fills to the appropriate mark. Make sure there are not any large air bubbles in the syringe. If there are, empty the syringe and try again. Step 4: Place the end of the syringe into the mouth against the cheek and carefully press the plunger down slowly to gently release the medicine. After use replace the bottle cap. Wash the syringe in warm water and allow to dry. Store out of the reach of children. Use in adults The usual dose for adults is 15 ml, 3 times daily. If your symptoms improve, your dose may be lowered to 10 ml, 3 times daily. Use in children and adolescents This medicine is not indicated in children aged less than 2 years. From 2 to 5 years old: 1.25 ml to 2.5 ml, 4 times daily. From 6 to 12 years old: 5 ml, 3 times daily in evenly spaced intervals. After using the syrup, close the bottle well. If you take more Carbocisteine than you should If upset stomach, nausea and vomiting occur, you should stop taking Carbocisteine and see the doctor. If you forget to take Carbocisteine If it is almost time to take the next dose, only take the next dose. If not, take the forgotten dose as soon as you remember. Do not take a double dose to make up for a forgotten dose. If you stop taking Carbocisteine Not applicable. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Uncommon: Digestive changes: nausea, vomiting and diarrhoea. Rare:
Hypersensitivity reactions, as hives and bronchospasm. Special attention in the asthmatic patients due to the risk of occurring bronchoconstriction (contraction of a muscle of the bronchial wall that leads to a reduction in the air passage). In these cases, the treatment should be stopped. Headache, muscle pain, dizziness, urinary incontinence, palpitations and breathlessness. Not known Allergic reactions, such as skin rash. Special attention in the patients with compromised thyroid function due to the risk of occurring hypothyroidism. Gastric discomfort, bronchorrhea (increased bronchial secretion).
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine.
Carbocisteine Do not store above 25°C.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle after "EXP." The expiry date refers to the last day of that month. Once the bottle is opened, Carbocisteine must be used within 3 months. If your syrup appears to be discoloured or shown any other signs of deterioration, take it back to your pharmacist who will advise you. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Carbocisteine contains
What Carbocisteine looks like and contents of the pack Carbocisteine is presented as a yellow- amber liquid with gooseberry flavour and a sweet taste. 200 ml or 300 ml bottles, of type Ill amber glass, with measuring device (oral syringe with 5 ml capacity).
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Amdeepcha Limited, 85 Yarmouth Road,
Manufacturer Laboratérios Basi – Industria Farmacéutica, S.A. Parque Industrial Manuel Lourengo Ferreira, Lotes 8, 15e 16 3450-232 Mortagua, Portugal
Blafield, Norwich,
Tel.: +351 231 920 250
Norfolk NR13 4LQ, United Kingdom
Fax: +351 231 921 055 E-mail: [email protected]
This leaflet was last revised in November
Marketing
2019
1/CS(IC)/05/1911/359.v2
Not all pack sizes may be marketed.
Carbocisteine 250 mg/ 5 ml syrup comes as oral solution containing 250mg / 5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Carbocisteine 250 mg/ 5 ml syrup is carbocisteine.
Medicines with the same active substance, strength and form include: Carbocisteine 250 mg/5 ml Sugar Free Adult Syrup, Carbocisteine 250 mg/5 ml oral solution, Carbocisteine 250mg/5ml sugar-free oral solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Carbocisteine 250 mg/ 5 ml syrup, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Carbocisteine is a mucolytic agent for the adjunctive therapy of respiratory tract disorders characterised by excessive, viscous mucus, including chronic obstructive airways disease.
Posology
Adults
Dosage is based upon an initial daily dosage of 2250 mg carbocisteine in divided doses, reducing to 1500 mg daily in divided doses when a satisfactory response is obtained e.g. for normal syrup 15 ml 3 times a day reducing to 10 ml 3 times a day.
Paediatric population
2 - 5 years: 1.25 - 2.5ml, four times a day.
6 - 12 years: 5 ml, three times a day.
Carbocisteine is contraindicated in children aged less than 2 years.
Method of administration
Use the measuring device to measure the appropriate amount, whether its use is for an adult or a child. The syringe for oral administration is graduated per 0.25ml. One graduation, 0.25ml corresponds to 12.5mg of carbocisteine.
How to use the syringe:
Step 1: Check the measurements on the side of the syringe to see how much to fill it.
Step 2: Push the syringe's plunger all the way down. Then put the tip of the syringe into the medicine bottle.
Step 3: Slowly pull back on the plunger until the syringe fills to the appropriate mark.
Make sure there are not any large air bubbles in the syringe. If there are, empty the syringe and try again.
Step 4: Place the end of the syringe into the mouth against the cheek and carefully press the plunger down slowly to gently release the medicine. After use replace the bottle cap. Wash the syringe in warm water and allow to dry. Store out of the reach of children.
Use in children less than 2 years of age.
Use in patients with active peptic ulceration.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special precautions:
- Asthmatic patients with a history of bronchospasm;
- Severe respiratory failure;
- Debilitated patients. By decreasing the cough reflex there is a risk of obstruction of the airways as a consequence of the secretions amount increase.
The use of Carbocisteine implies a decrease in the mucus viscosity and removal, either through the ciliary activity of the epithelium, or by the cough reflex. Therefore it is expected an increase of cough and sputum. This association of this medicine with antitussive medication is not recommended.
Caution is advised in the administration of carbocisteine in individuals susceptible to gastroduodenal ulcers, as mucolytics have the capacity to destroy the gastric mucosal barrier.
This medicine contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
This medicine contains methyl parahydroxybenzoate. May cause allergic reactions (possibly delayed).
No drug interactions have been identified
Pregnancy
Although tests in mammalian species have revealed no teratogenic effects, is not recommended during the first trimester of pregnancy.
Breast-feeding
It is unknown whether carbocisteine/metabolites are excreted in human milk.
Fertility
There is no known relevant data available on the effects of carbocisteine on fertility.
Carbocisteine has no or negligible influence on the ability to drive and use machines.
Adverse reactions listed by System Organ Class. Frequencies are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1000 to ≤1/100); rare (≥1/10,000 to ≤1/1,000); very rare (≤1/10,000); not known (cannot be estimated from the available data).
System Organ Class
Frequency
Adverse reaction
Cardiac disorders
Rare
Palpitations
Endocrine Disorders
Not known
Hypothyroidism.*
Gastrointestinal disorders
Uncommon
Nausea, vomiting and diarrhea.
Very rare
Gastrointestinal bleeding.
Not known
Gastric discomfort.
Immune system disorders
Rare
Urticaria and bronchospasm.**
Very rare
Rash.
Musculoskeletal and connective tissue disorders
Rare
Muscle pain
Nervous system disorders
Rare
Headache, dizziness, urinary incontinence, palpitations.
Respiratory, thoracic and mediastinal disorders
Rare
Shortness of breath.
Not known
Bronchorrhea.
Skin and subcutaneous tissue disorders
Not known
Stevens-Johnsons syndrome, erythema multiforme.
* Special attention in patients with compromised thyroid function due to the risk of transient hypothyroidism occurrence.
** Special attention in asthmatic patients due to the risk of bronchoconstriction occurrence (contraction of a muscle of the bronchial wall that leads to a reduction in airflow). In these cases, treatment discontinuation is recommended.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Gastrointestinal disturbance (gastralgias, nausea and vomiting) are the most likely symptoms of Carbocisteine overdosage.
Ask anything about Carbocisteine 250 mg/ 5 ml syrup. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.